Patient Outcomes and Long-Term Benefits Patient-reported outcomes demonstrate enhanced daytime energy and reduced sleep fragmentation after several months on GLP-1 and sleep apnea therapy
A viral insulin-like peptide is a natural competitive antagonist of the research-subject IGF-1 receptor
Alpha-synuclein, for example, contributes to the aggregation of beta-amyloid and tau compounds, tau compounds contribute to the aggregation of alpha-synuclein (Pan et al., 2021), and Lewy bodies have been observed not just in Parkinsons but in other neurodegenerative disease as well (Wong and Krainc, 2017)
Because retatrutide is not yet licensed for use in the UK, most people will not currently be taking it outside of a clinical trial
Rotate injection sites to prevent lipohypertrophy (a buildup of fat tissue at the injection site from repeated use)
A lack of this important antioxidant can also negatively impact vision, skin health, and clarity of thought [3]